BY CHRISTIAN BUNDGAARD
-
Novo Nordisk strikes back at Hims & Hers “We distance ourselves from the irresponsible and misleading advertisements”
Novo Nordisk discharges back at Hims & Hers with a United States paper advertisement.
-
Novartis buys back biotech company with Phase 3 candidate
Novartis was one of many founders of the reacquired firm.
-
Investor: AstraZeneca can succeed with small molecules and combinations in obesity treatment
AstraZeneca is presently striving to get in the financially rewarding weight-loss market as a rival to Novo Nordisk and Eli Lilly. Yet the approach is somewhat various.
-
Eli Lilly signs deal on MASH candidate potentially worth USD 630m
The prospect remains in stage 1.
-
CHMP recommends eight new drugs in January
Lundbeck is obtaining its tag increased for Rexulti.
-
Bavarian Nordic’s chikungunya vaccine set for approval
The favorable referral from CHMP puts on individuals aged 12 years and older.
-
Novo Holdings is by far the largest taxpayer in Denmark
On the whole, Danish firms added DKK 101.7 bn in company tax obligation in 2023.
-
FDA approves first non-opiod pain reliever in new class
The therapy will certainly set you back USD 15.50 per tablet computer or about USD 31 each day.
-
Ambu’s final report reveals little news as bank predicts no impact on share price
The business’s assistance upgrade and initial numbers were compensated with a share rate rise of over 17%, so there should not be much of a rate response when the stock excha…
-
Coloplast abused its dominant position in Denmark, rules authority
Danish competitors authority locates that Coloplast has actually utilized its leading setting to press opponents out of the component of the marketplace providing communities with …
